Xspray Pharma publishes its annual report for 2021

Regulatory press release 2022-03-25

“In 2021, we once again confirmed that Xspray Pharma’s unique technology platform can produce amorphous versions of protein kinase inhibitors. Having our processes in place means that we can shorten the development time for new products. I look forward to an intensive and productive 2022, during which Xspray Pharma’s organization will develop and mature, and to the growth of our pipeline. In parallel to this, the commercial preparations are well underway, as is the FDA’s review process of our first product candidate.

We have learned a lot during the past year, and consequently we took a strategically important decision to focus on improved pharmaceuticals. This is a decision that simplifies and streamlines our operations. Focus will be on identification and development of product candidates where our unique technology can be used to achieve improved pharmaceuticals”, said Per Andersson, CEO of Xspray Pharma.

The annual report is attached, and can also be downloaded from the company's website, www.xspraypharma.com.

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development. Xspray Pharma uses its innovative, patented RightSize™ technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs of PKIs already marketed for the treatment of cancer, which numbered to 72 in the end of 2021. The company’s leading product candidates, Dasynoc (former HyNap-Dasa), HyNap-Nilo, and HyNap-Sora, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Tasigna® (nilotinib) and Nexavar® (sorafenib). HyNap-Dasa is being developed as an improved version of Sprycel. HyNap-Nilo is being developed as an improved version of Tasigna and has has received orphan drug status from the US FDA. HyNap-Sora is being developed as an improved version of Nexavar®.

The company has patented manufacturing technology, equipment, and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com